November #149 : Starting Out Late? - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Free At Last?

It's a Girl!




Condomless Sex? Maybe Not Yet

Meditation Matters

Boys and Girls Together

Med Alert-November 2008

From the Inside: Strength to Spare

Ritonavir News

A Liver-Cleansing Herb’s Benefits Begin to Bloom

Sweet Spot

Bottoms Up

Starting Out Late?

Eat Well, Pay Little

Is Organic Food Worth the Splurge?

Coats of Many Colors




Prison Break

Ladies First

POS/NEG

Shout Out!

In Their Words

You Said It...

Life’s Rich Pageant

How to... Disclose in the Heat of the Moment




Editor's Letter-November 2008

Your Feedback-November 2008



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

November 2008


Starting Out Late?

by Laura Whitehorn

New stats reveal that about one third of people who test positive for HIV in many U.S. cities do so with low CD4 counts and often with an AIDS-related complication such as an opportunistic infection (OI). New information can help the newly diagnosed get the most benefit from HIV care and treatment. Two recent developments:

  • A 189-person study unveiled this summer at the XVII International AIDS Conference suggests that for people with low CD4 counts (in the double digits) who are starting their first HIV combo, Sustiva (efavirenz, a non-nuke) may be a better choice than Kaletra (lopinavir/ritonavir, a protease inhibitor plus booster). For people who are starting HIV meds when their CD4 cell counts are higher, the two meds work equally well at suppressing HIV.
  • The Department of Health and Human Services recently issued new guidelines for treating OIs—like some forms of TB and pneumonia that attack immune systems weakened by HIV. The guidelines remind providers to watch for immune reconstitution inflammatory syndrome (IRIS), a flare-up of OI symptoms that occurs when HIV meds suddenly restore damaged immune systems. IRIS symptoms are often treated differently from those of OIs.

Search: CD4 counts, International AIDS Conference, The Department of Health and Human Services


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    dversescott
    Baltimore
    Maryland


    InDefaultOf
    Seattle
    Washington


    Sexynyrican
    Brooklyn
    New York

This could be you!
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.